INTRODUCTION
============

Although laparoscopic cholecystectomy (LC) has become the standard for gallbladder removal, there is still debate as to the most effective and efficient method of clearing choledocholithiasis. One frequent clinical scenario in which the clinician must decide the most appropriate treatment methodology is the patient with preoperatively suspected choledocholithiasis. Options include open common bile duct (CBD) exploration, laparoscopic CBD clearance with postoperative endoscopic retrograde cholangiopancreaticography (ERCP) or open CBD exploration reserved for laparoscopic failures. Another approach is preoperative ERCP followed by LC. Because of the higher morbidity associated with open cholecystectomy compared to LC, open CBD exploration as a firstline therapy for patients with suspected choledocholithiasis has fallen out of favor. As surgeons have improved their laparoscopic skills and laparoscopic technology continues to advance, there has been a steady increase in the number of series promoting laparoscopic CBD techniques as the initial procedure of choice in patients suspected of having CBD stones.^[@B1]--[@B9]^ In this treatment plan, if laparoscopic techniques fail, the surgeon must either convert to open CBD exploration with increased morbidity or rely on postoperative ERCP. Many centers do not have the laparoscopic technology or expertise to reliably clear CBD stones. In other centers, timely postoperative ERCP is difficult to obtain from a logistical standpoint. Thus, many institutions still rely on preoperative ERCP in cases of suspected CBD stones.^[@B10],[@B11]^

Advocates of preoperative ERCP are many.^[@B12]--[@B22]^ However, a liberal use of preoperative ERCP based on risk factors for choledocholithiasis can result in a high number of nontherapeutic ERCPs (25-76%).^[@B11]--[@B13],[@B18],[@B21]--[@B27]^ Well established risk factors for CBD stones include age, cholangitis, jaundice, elevated liver function tests (LFTs), gallstone pancreatitis, a prior history of CBD stones, and ultrasonography (US) findings of choledocholithiasis or a dilated CBD.^[@B28],[@B29]^ Recently, much effort has been expended to better define the clinical risk factors that most accurately predict CBD stones in order to avoid unnecessary ERCPs.^[@B13],[@B30]--[@B34]^ The results have not been consistent. Some have found US findings necessary to develop a good predictive model,^[@B11],[@B35],[@B36]^ while others have found US findings to be an unreliable predictor of CBD stones.^[@B37]^ Several series conclude that only a combination of elevated LFTs and US findings will most accurately predict CBD stones.^[@B13],[@B28],[@B32]^

In our institution, we do not have postoperative ERCP readily available, and we are still in the process of developing our laparoscopic CBD expertise. Thus, patients whom we feel are at high risk for CBD stones are subjected to preoperative ERCP with endoscopic sphincterotomy and stone extraction, as indicated, followed by LC. In this series, we analyze the accuracy of our clinical risk factors in predicting CBD stones, the success of preoperative ERCP at clearing the CBD, and, if CBD stones were left behind after ERCP (detected on intraoperative cholangiography), whether we were able to clear them laparoscopically.

MATERIALS AND METHODS
=====================

The medical records of all patients at Kern Medical Center with gallbladder disease who had preoperative ERCP for suspected choledocholithiasis from January 1997 through July 1998 were reviewed. Each patient\'s age, sex, clinical presentation including laboratory values and US findings were recorded. The specific findings that led the physician to suspect choledocholithiasis and prompted preoperative ERCP were noted. The ERCP procedure details, findings and conclusions were examined, as were the intraoperative finding and procedure details. We recorded whether CBD stones were found during ERCP and, if present, how these stones were cleared. We also noted whether the endoscopist felt CBD stone clearance was complete or not. Any complication related to ERCP was noted. All patients had LC performed within 24 hours of ERCP. Intraoperative cholangiogram findings were analyzed as to the presence of CBD stones and, if present, whether they were cleared successfully. The intraoperative techniques to clear the CBD were noted.

RESULTS
=======

Seventeen patients had preoperative ERCP for suspected choledocholithiasis, followed by LC over the 19-month period reviewed. The mean age of patients with confirmed CBD stones was 33 years (range 15-58) and 38 years (range 22-54) in patients with no CBD stones found on ERCP. Four of the 17 patients were males. All patients were admitted to the hospital for acute biliary symptoms. Clinical presentations included 7 patients with biliary pancreatitis, 2 with cholangitis, and 8 with symptomatic cholelithiasis plus suspected biliary obstruction. Gallstones were visualized on US in 15 of 17 patients. The endoscopist was able to successfully cannulate the papillae and complete the ERCP in all 17 patients. There were no complications or deaths related to the endoscopic procedure in this series.

Reasons for suspected choledocholithiasis that led to preoperative ERCP included gallstone pancreatitis in 7, elevated serum bilirubin level (\>1.7 mg/dl) in 13, elevated alkaline phosphatase level (\>107 U/L) in 14, US finding of choledocholithiasis in 3 and dilated CBD in 10 (\>7 mm). Sixteen of 17 patients had more than one of the above risk factors for choledocholithiasis present at admission **([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"})**.

###### 

Risk factors in patients with no CBD stone found on ERCP.

  PATIENT                              SB ≠   AP ≠   GSP   CBD STONE US   CBD DILATED ON US
  ------------------------------------ ------ ------ ----- -------------- -------------------
  1[\*](#TF1-1){ref-type="table-fn"}   Yes    Yes    Yes                  
  2[†](#TF1-2){ref-type="table-fn"}           Yes    Yes                  
  3[†](#TF1-2){ref-type="table-fn"}                  Yes   Yes            Yes
  4[†](#TF1-2){ref-type="table-fn"}           Yes    Yes                  
  5[†](#TF1-2){ref-type="table-fn"}                                       Yes

Patient admitted to General Surgery.

Patient admitted to Internal Medicine.

SB=serum bilirubin; AP=alkaline phosphatase; GSP=gallstone pancreatitits; US=ultrasound; CBD=common bile duct.

###### 

Risk factors in patients with CBD stone found on ERCP.

  PATIENT                               SB ≠   AP ≠   GSP   CBD STONE US   CBD DILATED ON US
  ------------------------------------- ------ ------ ----- -------------- -------------------
  1[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes                         Yes
  2[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes    Yes   Yes            Yes
  3[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes                         
  4[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes                         
  5[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes    Yes                  
  6[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes                         
  7[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes    Yes                  Yes
  8[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes                         Yes
  9[\*](#TF2-1){ref-type="table-fn"}    Yes    Yes                         
  10[\*](#TF2-1){ref-type="table-fn"}   Yes    Yes                         Yes
  11[\*](#TF2-1){ref-type="table-fn"}   Yes                 Yes            Yes
  12[\*](#TF2-1){ref-type="table-fn"}   Yes    Yes                         Yes

Patient admitted to General Surgery.

SB=serum bilirubin; AP=alkaline phosphatase; GSP=gallstone pancreatitits; US=ultrasound; CBD=common bile duct.

No CBD stones were found on ERCP in 5 of 17 patients (29%). Of these 5 patients, the intraoperative cholangiogram confirmed no choledocholithiasis in 2, while cholangiogram was not performed in the other 3 **([Figure 1](#F1){ref-type="fig"})**. The risk factors for choledocholithiasis, which were present as well as those not present in the patients who did not have CBD stones found on ERCP, are presented in **[Table 1](#T1){ref-type="table"}**.

![Patients with suspected choledocholithiasis who underwent ERCP prior to laparoscopic cholecystectomy. CBD=common bile duct; IOC=intraoperative cholangiogram.](jsls-4-2-109-g01){#F1}

Common bile duct stones were detected on ERCP in 12 of 17 patients (71%). The risk factors for choledocholithiasis, noted in these 12 patients, are presented in **[Table 2](#T2){ref-type="table"}**. In all 12 patients, sphincterotomy with stone extraction was performed and, in each case, the endoscopist reported a fully cleared CBD. Intraoperative cholangiogram was performed during subsequent LC in 9 of the 12 patients who had stones found and reportedly cleared by ERCP. Choledocholithiasis was still present in 4 of these 9 patients **([Figure 1](#F1){ref-type="fig"})**. Laparoscopic techniques (all transcystic) successfully cleared the CBD in 3 patients. The fourth patient required open CBD exploration for successful clearance.

DISCUSSION
==========

Before the introduction of LC, the use of ERCP in patients with gallbladder disease was reserved for patients with severe biliary pancreatitis, acute suppurative cholangitis, poor operative candidates with suspected CBD stones or for postoperative retained stones. Open CBD exploration added little to open cholecystectomy alone in terms of morbidity or mortality. However, open CBD exploration compared to LC substantially lengthens morbidity, hospital stay, and return to work time. This has resulted in much interest in methods to clear the CBD by less invasive means. The major options when CBD stones are suspected include preoperative ERCP, laparoscopic CBD clearance techniques, or postoperative ERCP if laparoscopic methods fail or are not available. The optimal approach to patients with suspected CBD stones is uncertain and depends upon local expertise in laparoscopy, availability of equipment, as well as the availability and expertise in ERCP.

In 1993, the NIH Consensus statement recommended preoperative ERCP or transhepatic cholangiography for all patients with clinical suspicion for CBD stones. This led to a high number of therapeutic and nontherapeutic ERCP\'s.^[@B38]^ Several centers report ERCP to have a high diagnostic success rate (76-97%)^[@B12],[@B19],[@B39]--[@B41]^ and an inability to cannulate rate of just 5%.^[@B24],[@B39]^ In our series, endoscopists had a cannulation rate of 100%. Major centers report impressive ductal clearance rates of more than 90%.^[@B11],[@B12],[@B26],[@B42]--[@B44]^ However, Poole and Cuschieri pointed out that data collected from major centers probably underestimates the actual endoscopic stone extraction failure rate and that, in European trials, the preoperative ERCP ductal clearance failure rate is approximately 20%.^[@B10],[@B45]^ Koo reported a small series in which endoscopists supposedly cleared the CBD of stones, yet 43% were found to have residual stones on intraoperative cholangiography.^[@B30]^ In our series, of the 12 patients whom the endoscopist reported to have endoscopically cleared the CBD stones, 4 (33%) were subsequently found to have choledocholithiasis on intraoperative cholangiography. We suspect that the stones undetected during ERCP were present in the intrahepatic ducts and thus difficult to visualize. Subsequently, these stones migrated into the CBD and were successfully detected during intraoperative cholangiography.

In an institution such as our own, in which ERCP is performed prior to LC in patients with suspected CBD stones, the critical element in avoiding unnecessary ERCP and its inherent risk and cost is the effectiveness of CBD stone prediction. Complications of ERCP occur approximately 10% of the time, with a mortality rate of 1-3%.^[@B46]--[@B48]^ The most common of the complications, post-ERCP pancreatitis, occurs from 1-5.5% of the time, with 10% of those who develop the complication requiring surgical intervention.^[@B46],[@B49]^ In our series, we were fortunate to have no complications related to ERCP and no mortality.

The incidence of CBD stones in unselected patients undergoing elective LC has been quoted as 5-20%.^[@B27],[@B30],[@B50]--[@B55]^ However, in patients thought to be at low risk for CBD stones, the rate of choledocholithiasis found on routine intraoperative cholangiogram is reported to be 1.7%.^[@B26]^ To better define the most accurate clinical risk factors for choledocholithiasis and thereby avoid subjecting patients to unnecessary preoperative ERCP, several models have been developed. Barkin found that a combination of risk factors including age, elevated bilirubin, and US findings of a dilated duct and a CBD stone produced a 94% specificity of CBD stone presence.^[@B32]^ He also found that if all four risk factors were absent, then the chance of a CBD stone being present was only 8%.^[@B32]^ His model is clinically limited because most patients do not have all four risk factors either present or absent. Robertson\'s model using age, jaundice, albumin, and US findings produced a 75% specificity and 89% sensitivity for CBD stones.^[@B13]^ Trondsen developed a model using age and a combination of several LFTs to accurately predict CBD stones with a 3.7% false positive rate and a 1.8% false negative rate.^[@B33]^ Robertson and Lacaine both concluded that of all the LFTs, alkaline phosphatase was the most important in predicting CBD stones, but Robertson emphasized that a single elevated LFT was not a good predictor.^[@B13],[@B31]^ Saltztein found that the only combination of risk factors that accurately predicted CBD stones was a combination of elevated bilirubin and elevated alkaline phosphatase.^[@B34]^ In our series, we found a normal serum bilirubin to be the best predictor of the absence of CBD stones with a false negative rate of 0/4 (0%). Of the 4 patients who had a normal bilirubin but other risk factors present, none were found to have CBD stones **([Table 1](#T1){ref-type="table"})**. An elevated bilirubin level in our series was the best predictor of the presence of CBD stones. A total of 13 patients had an elevated bilirubin and, of those, 12 of 13 (92%) had CBD stones found (a false positive rate of 8%). In this series, LFTs other than bilirubin did not accurately predict CBD stones, nor did age. Three patients had a normal alkaline phosphatase and, of those, one had a CBD stone (a false negative rate of 33%). Fourteen patients had an elevated alkaline phosphatase, but only 11 had CBD stones (a false positive rate of 21%). In our series, biliary dilatation found on US had a 22% false positive rate (2/9), while a normal-sized ductal system did not accurately predict the absence of CBD stones (false negative rate of 63%). Interestingly, each of the three patients who had false positive US findings also had a normal bilirubin, further supporting the negative predictive value of a normal bilirubin.

Many authors have demonstrated the overall low incidence of CBD stones found in gallstone pancreatitis patients, especially if one delays ERCP or intraoperative cholangiography for more than 48 hours from the time of presentation or until the pancreatitis has resolved.^[@B12],[@B56]--[@B59]^ Others have concluded that preoperative ERCP in patients with biliary pancreatitis is only warranted for persistent elevation of LFTs or in patients with severe pancreatitis who do not quickly improve.^[@B60]^ Our findings support these observations. In our 7 biliary pancreatitis patients, only 3 (43%) had CBD stones detected and, of those, all 3 had an elevated serum bilirubin level, further supporting the predictive value of bilirubin in our institution. In total, of the 17 patients subjected to preoperative ERCP, 12 were confirmed to have choledocholithiasis (71%). Of note, at our institution, the Department of Surgery typically obtains preoperative ERCP based on a persistently elevated bilirubin level. Of the 5 patients who were found to have no CBD stones (received unnecessary preoperative ERCP), 4 were admitted to the Internal Medicine service. They each had a normal serum bilirubin, but preoperative ERCP was ordered based on the presence of other risk factors. Had these patients been on the Surgery service, they most likely would not have had preoperative ERCP because they had a normal serum bilirubin.

We, like others, have found laparoscopic CBD clearance an effective alternative to open CBD exploration.^[@B1],[@B2],[@B8]^ Advances in technology, as well as advanced laparoscopic skills, have made possible transcystic and, more recently, supraduodenal choledochotomy with CBD clearance.^[@B3],[@B4],[@B9]^ As the success rate of laparoscopic CBD clearance has improved to more than 80%, many surgeons bypass the preoperative ERCP in patients with suspected CBD stones and, if found on intraoperative cholangiography, CBD stones are cleared laparoscopically.^[@B2],[@B5]--[@B8]^ Erickson, using decision tree analysis and existing data in the literature, determined that the best management scheme in terms of cost and morbidity in patients with predicted CBD stones was laparoscopic CBD clearance with postoperative ERCP reserved for laparoscopic failures. If the ability of the institution to accurately predict CBD stones was high, preoperative ERCP followed by laparoscopic CBD exploration for ERCP failures was an equally effective strategy. Finally, he found that if postoperative ERCP was not readily available, then preoperative ERCP followed by LC was the preferred approach.^[@B61]^

Others, like us, reserve laparoscopic CBD techniques for unexpected choledocholithiasis found intra-operatively and to ERCP failures.^[@B10],[@B62]^ In our series, we found residual choledocholithiasis in 4 patients. These CBD stones were successfully cleared with transcystic laparoscopic techniques in 3 of 4 (75%) patients. Other treatment options for residual CBD stones post ERCP include expectant therapy, repeat postoperative ERCP, or open CBD clearance. Factors which support spontaneous postoperative passage of CBD stones include a single small stone, no significant distal CBD stricture, duodenal filling during cholangiogram, the serum bilirubin not rising since the ERCP and the gastroenterologist feeling an adequate sphincterotomy has been performed. Studies have shown that a stone greater than 1 cm or multiple stones are significantly more difficult to clear with ERCP and sphincterotomy, so we would not rely on repeat postoperative ERCP for stone clearance nor would we necessarily expect these to pass spontaneously.^[@B63]--[@B64]^ Therefore, if we detect a residual stone greater than 1 cm or multiple stones during intraoperative cholangiography, we are inclined to convert to open CBD exploration if laparoscopic CBD techniques have failed.

CONCLUSIONS
===========

In patients with a high suspicion for choledocholithiasis, preoperative ERCP followed by LC is an effective strategy. Unnecessary ERCP can be avoided if strict clinical criteria to reliably predict CBD stones is established and followed (serum bilirubin in our institution). Although ERCP cannulation rate and the detection rate of choledocholithiasis is high, residual stones are not uncommon even after presumed successful ERCP. These stones can be detected with intraoperative cholangiography and, if found, can be treated effectively with laparoscopic techniques if the surgeon feels the stones will not pass spontaneously.
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